Discover
NVCR
NovoCure Limited
15.78
2 x 11.40
2 x 19.68
bid
ask
+
0.63
4.16%
2 @ 05:16 AM
15.88 +0.10 (0.66%)
| Ytd | 22.04% | |
| 1y | -11.74% |
15.29
day range
16.00
9.82
52 week range
18.92
| Open | 15.29 | Prev Close | 15.15 | Low | 15.29 | High | 16.00 | Mkt Cap | 1.83B |
| Vol | 1.20M | Avg Vol | 1.64M | EPS | -1.53 | P/E | N/A | Forward P/E | -12.70 |
| Beta | 0.92 | Short Ratio | 6.44 | Inst. Own | 88.34% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 07-23 | 50-d Avg | 16.14 | 200-d Avg | 13.46 | 1yr Est | 26.00 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-04-30 | 2026-03 | 0 | N/A | -0.22 | -55.00% |
| 2026-02-26 | 2025-12 | 0 | N/A | 0.19 | 46.34% |
| 2025-10-30 | 2025-09 | 0 | N/A | 0.09 | 21.43% |
| 2025-07-24 | 2025-06 | 0 | N/A | 0.03 | 7.69% |
| 2025-04-24 | 2025-03 | 0 | N/A | 0.16 | 34.04% |
| 2025-02-27 | 2024-12 | 0 | N/A | -0.27 | -79.41% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-06-18 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2026-05-04 | Wells Fargo | Upgrade | Equal-Weight | Equal-Weight |
| 2026-05-01 | Evercore ISI Group | Upgrade | Outperform | Outperform |
| 2026-04-16 | Wedbush | Upgrade | Neutral | Neutral |
| 2026-02-26 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2026-02-12 | HC Wainwright & Co. | Upgrade | Buy | Buy |
Profile
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2026-03-02 | BEN ARYE BARAK | General Counsel | 242.45K | Stock Award(Grant) |
| 2026-03-03 | BRACKMANN CHRISTOPH | Chief Financial Officer | 182.84K | Sale |
| 2026-02-26 | CORDOVA ASHLEY | Former | 440.21K | Stock Award(Grant) |
| 2025-12-30 | DANZIGER ASAF | Director | 416.47K | Stock Award(Grant) |
| 2026-03-02 | DOYLE WILLIAM F | Officer and Director | 328.40K | Stock Award(Grant) |
| 2026-06-03 | LEONARD FRANCIS XAVIER II | Chief Executive Officer | 459.52K | Sale |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | FMR, LLC | 17.07M | 269.35M | 14.74% |
| 2026-03-30 | Blackrock Inc. | 13.19M | 208.20M | 11.39% |
| 2026-03-30 | Soleus Capital Management, L.P. | 10.49M | 165.57M | 9.06% |
| 2026-03-30 | Vanguard Portfolio Management LLC | 6.25M | 98.65M | 5.40% |
| 2026-03-30 | Vanguard Capital Management LLC | 4.68M | 73.88M | 4.04% |
| 2026-03-30 | Morgan Stanley | 4.54M | 71.67M | 3.92% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-05-30 | Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 5.88M | 92.81M | 5.08% |
| 2026-03-30 | VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.36M | 53.01M | 2.90% |
| 2026-03-30 | VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.49M | 39.36M | 2.15% |
| 2026-04-29 | iShares Trust-iShares Russell 2000 ETF | 2.39M | 37.68M | 2.06% |
| 2026-05-30 | Fidelity Mt. Vernon Street Trust-Fidelity Growth Company K6 Fund | 1.73M | 27.37M | 1.50% |
| 2026-05-30 | Fidelity Mt. Vernon Street Trust-Fidelity Series Growth Company Fund | 1.55M | 24.47M | 1.34% |